The predictive value of PI3K signaling pathway in ovarian cancer prognosis: a meta-analysis

R. Wei, L. Li

Guangxi Medical University, Nanning, Guangxi, China. lili@gxmu.edu.cn

---

• Oncology

OBJECTIVE: The aim of the study was to comprehensively assess the clinical significance of the Phosphoinositide 3-kinase (PI3K) signaling pathway in ovarian cancer patients, we conducted a meticulous meta-analysis utilizing individual studies.

MATERIALS AND METHODS: In this meta-analysis, publications through PubMed, Embase, and Cochrane Library databases were searched from inception to December 2022. In this study, only published studies related to the PI3K signaling pathway and prognosis of ovarian cancer patients were included, excluding unpublished literature, incomplete data, animal experiments, literature reviews, and systematic studies. All data were processed by STATA15.1 statistical software.

RESULTS: Previous studies found that PI3K activation was closely related to poor prognosis of ovarian cancer cells [Hazard Ratio (HR)=1.67, 95% CI: 1.03-2.69, p=0.038], but not significantly related to disease-free prognosis (HR=1.07, 95% CI: 0.12-9.54, p=0.950). Our previous study found that PI3K pathway activation significantly reduced survival in >50% of stage II/III ovarian cancer cells (HR=2.07, 95% CI: 1.17-3.66, p=0.012). Our previous study found that PI3K activation level was not strongly associated with the survival of osteosarcoma in the European population (HR=1.35, 95% CI: 0.24-7.60, p=0.733), while in the Asian population, PI3K activation level was not strongly associated with the survival of osteosarcoma (HR=1.47, 95% CI: 1.15-1.87, p=0.023).

CONCLUSIONS: PI3K can be used as a predictor of prognosis for ovarian cancer, especially in advanced ovarian cancer and Asian patients. Activation of PI3K signaling is associated with poor prognosis in ovarian cancer.

Free PDF Download